{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:17:35Z","timestamp":1790806655923,"version":"4.1.0"},"reference-count":130,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,3,17]],"date-time":"2018-03-17T00:00:00Z","timestamp":1521244800000},"content-version":"am","delay-in-days":350,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["IZ32Z0_157953"],"award-info":[{"award-number":["IZ32Z0_157953"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Aging"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.neurobiolaging.2016.07.012","type":"journal-article","created":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T01:18:01Z","timestamp":1489713481000},"page":"214-227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"special_numbering":"C","title":["Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework"],"prefix":"10.1016","volume":"52","author":[{"given":"Konstantinos","family":"Chiotis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Saint-Aubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Boccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Gietl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Picco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Varrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2422-698X","authenticated-orcid":false,"given":"Valentina","family":"Garibotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Herholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Nobili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agneta","family":"Nordberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni B.","family":"Frisoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Winblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Clifford R","family":"Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib1","series-title":"ClinicalTrialsRegister.eu [Internet]","article-title":"The clinical value of amyloid imaging with [18F]-AV45 in a population of memory clinic patients","year":"1995"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib2","series-title":"ClinicalTrialsRegister.eu [Internet]","article-title":"Amyloid-PET as a diagnostic marker in daily practice","year":"1995"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00259-015-3156-9","article-title":"Amyloid imaging in cognitively normal older adults: comparison between (18)F-flutemetamol and (11)C-Pittsburgh compound B","volume":"43","author":"Adamczuk","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib4","doi-asserted-by":"crossref","first-page":"RC189","DOI":"10.1523\/JNEUROSCI.21-24-j0004.2001","article-title":"Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease","volume":"21","author":"Agdeppa","year":"2001","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib5","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/archneur.65.11.1509","article-title":"Frequent amyloid deposition without significant cognitive impairment among the elderly","volume":"65","author":"Aizenstein","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib6","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimer's Demen."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1001\/archneur.64.3.431","article-title":"Molecular imaging with Pittsburgh compound B confirmed at autopsy: a case report","volume":"64","author":"Bacskai","year":"2007","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib8","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1007\/s00259-011-1821-1","article-title":"Individualized quantification of brain beta-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls","volume":"38","author":"Barthel","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib9","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2967\/jnumed.112.107185","article-title":"PET quantification of 18F-florbetaben binding to beta-amyloid deposits in human brains","volume":"54","author":"Becker","year":"2013","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1212\/WNL.59.2.198","article-title":"Natural history of mild cognitive impairment in older persons","volume":"59","author":"Bennett","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.tips.2015.03.002","article-title":"Amyloid biomarkers in Alzheimer's disease","volume":"36","author":"Blennow","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neurobiolaging.2017.01.021","article-title":"The Geneva Task Force for the Roadmap of Alzheimer\u2019s Biomarkers, The Biomarker-based Diagnosis of Alzheimer\u2019s Disease","volume":"52","author":"Boccardi","year":"2017","journal-title":"2 \u2013 Lessons From Oncology, Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib13","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1007\/s00259-013-2415-x","article-title":"Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine","volume":"40","author":"Booij","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1600-0404.1996.tb05866.x","article-title":"Evolution of the neuropathology of Alzheimer's disease","volume":"165","author":"Braak","year":"1996","journal-title":"Acta Neurol. Scand. Suppl."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib15","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00259-013-2478-8","article-title":"[11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment","volume":"40","author":"Bruck","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib16","first-page":"153","article-title":"The Geneva Task Force for the Roadmap of Alzheimer\u2019s Biomarkers, Clinical validity of delayed recall tests as a gateway-biomarker for Alzheimer\u2019s disease in the context of a structured 5-phase development framework Neurobiol","volume":"52","author":"Cerami","year":"2017","journal-title":"Aging"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib17","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1212\/WNL.0b013e318246d67a","article-title":"Accelerated cortical atrophy in cognitively normal elderly with high beta-amyloid deposition","volume":"78","author":"Chetelat","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib18","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1007\/s00259-015-3115-5","article-title":"Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging","volume":"42","author":"Chiotis","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib19","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3233\/JAD-121927","article-title":"Amyloid deposition in early onset versus late onset Alzheimer's disease","volume":"35","author":"Cho","year":"2013","journal-title":"J.\u00a0Alzheimer's Dis."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib20","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2967\/jnumed.109.065284","article-title":"Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain","volume":"50","author":"Choi","year":"2009","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib21","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/JGP.0b013e318202bf3a","article-title":"Relationship of amyloid-beta burden with age-at-onset in Alzheimer disease","volume":"19","author":"Choo","year":"2011","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib22","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","article-title":"Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study","volume":"11","author":"Clark","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.neuroimage.2013.01.015","article-title":"Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches","volume":"71","author":"Cohen","year":"2013","journal-title":"NeuroImage"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib24","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families","volume":"261","author":"Corder","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib25","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.0b013e3181a2e8d0","article-title":"Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease","volume":"72","author":"Drzezga","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib26","series-title":"9th Human Amyloid Imaging Meeting","first-page":"P19","article-title":"Should the threshold for a positive amyloid pet scan be adjusted for ApoE carrier status, age, level of cognitive and functional impairment?","author":"Duara","year":"2015"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib27","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib28","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/cercor\/bhr271","article-title":"CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects","volume":"22","author":"Ewers","year":"2012","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib29","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1001\/archneurol.2011.150","article-title":"Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease","volume":"68","author":"Fleisher","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2012.04.017","article-title":"Apolipoprotein E epsilon4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease","volume":"34","author":"Fleisher","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib31","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1212\/WNL.0b013e31829d86e8","article-title":"Imaging markers for Alzheimer disease: which vs how","volume":"81","author":"Frisoni","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib32","first-page":"119","article-title":"A roadmap to the use of biomarkers for the diagnosis of Alzheimer\u2019s disease in clinical practice: the Italian inter-societal consensus, Neurobiol","volume":"52","author":"Frisoni","year":"2017","journal-title":"Aging"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib33","first-page":"183","article-title":"The Geneva Task Force for the Roadmap of Alzheimer\u2019s Biomarkers, Maturity of FDG-PET as a biomarker for Alzheimer\u2019s disease in the context of a structured 5 \u2013phase development framework, Neurobiol","volume":"52","author":"Garibotto","year":"2017","journal-title":"Aging"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib34","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00259-013-2564-y","article-title":"[18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease","volume":"41","author":"Hatashita","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib35","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00259-015-3208-1","article-title":"Imaging beta-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis","volume":"43","author":"Heurling","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","article-title":"National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease","volume":"8","author":"Hyman","year":"2012","journal-title":"Alzheimer's Demen."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib37","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005072-199710000-00002","article-title":"Editorial on consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute working group on diagnostic criteria for the neuropathological assessment of Alzheimer disease","volume":"56","author":"Hyman","year":"1997","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib38","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/brain\/awn016","article-title":"Post-mortem correlates of in\u00a0vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease","volume":"131","author":"Ikonomovic","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib39","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/brain\/awm336","article-title":"11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment","volume":"131","author":"Jack","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib40","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1093\/brain\/awq277","article-title":"Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease","volume":"133","author":"Jack","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib41","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S1474-4422(14)70194-2","article-title":"Age-specific population frequencies of cerebral beta-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study","volume":"13","author":"Jack","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib42","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","article-title":"Prevalence of cerebral amyloid pathology in persons without dementia a meta-analysis","volume":"313","author":"Jansen","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib43","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2967\/jnumed.113.120618","article-title":"Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association","volume":"54","author":"Johnson","year":"2013","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib44","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.jalz.2012.10.007","article-title":"Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging","volume":"9","author":"Johnson","year":"2013","journal-title":"Alzheimer's Demen."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib45","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2967\/jnumed.111.090340","article-title":"Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects","volume":"53","author":"Joshi","year":"2012","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib46","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/brain\/awq349","article-title":"Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease","volume":"134","author":"Kadir","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib47","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/ana.21212","article-title":"Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease","volume":"63","author":"Kemppainen","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib48","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00259-013-2562-0","article-title":"Five-year follow-up of 11C-PIB uptake in Alzheimer's disease and MCI","volume":"41","author":"Kemppainen","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib49","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimer's Demen."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib51","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1159\/000163927","article-title":"PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment","volume":"26","author":"Koivunen","year":"2008","journal-title":"Demen. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib52","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1212\/WNL.0b013e318212015e","article-title":"Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study","volume":"76","author":"Koivunen","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib53","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1001\/archneurol.2011.2748","article-title":"Association of lifetime cognitive engagement and low beta-amyloid deposition","volume":"69","author":"Landau","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib54","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/ana.23650","article-title":"Amyloid deposition, hypometabolism, and longitudinal cognitive decline","volume":"72","author":"Landau","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib55","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2967\/jnumed.112.109009","article-title":"Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods","volume":"54","author":"Landau","year":"2013","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib56","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/ana.23908","article-title":"Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid","volume":"74","author":"Landau","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib57","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1007\/s00259-014-2753-3","article-title":"Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers","volume":"41","author":"Landau","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib58","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/jnnp-2013-305858","article-title":"Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients","volume":"85","author":"Lehmann","year":"2014","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib59","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/2051-5960-2-46","article-title":"Diagnostic effectiveness of quantitative [(1)(8)F]flutemetamol PET imaging for detection of fibrillar amyloid beta using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus","volume":"2","author":"Leinonen","year":"2014","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib60","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3233\/JAD-142952","article-title":"Concordance and diagnostic accuracy of [11C]PIB PET and cerebrospinal fluid biomarkers in a sample of patients with mild cognitive impairment and Alzheimer's disease","volume":"45","author":"Leuzy","year":"2015","journal-title":"J.\u00a0Alzheimer's Dis."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib61","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1093\/brain\/aww160","article-title":"Pittsburgh compound B imaging and cerebrospinal fluid amyloid-\u03b2 in a multicentre European memory clinic study","volume":"139","author":"Leuzy","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib62","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.nucmedbio.2010.05.001","article-title":"Optimization of automated radiosynthesis of [18F]AV-45: a new PET imaging agent for Alzheimer's disease","volume":"37","author":"Liu","year":"2010","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib63","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1097\/MD.0000000000000150","article-title":"Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis","volume":"93","author":"Ma","year":"2014","journal-title":"Medicine"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib64","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","article-title":"Amyloid plaque core protein in Alzheimer disease and Down syndrome","volume":"82","author":"Masters","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib65","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.semnuclmed.2012.07.001","article-title":"Development of positron emission tomography beta-amyloid plaque imaging agents","volume":"42","author":"Mathis","year":"2012","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib66","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1021\/jm030026b","article-title":"Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents","volume":"46","author":"Mathis","year":"2003","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib67","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/acn3.81","article-title":"Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease","volume":"1","author":"Mattsson","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib68","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.neurobiolaging.2016.02.034","article-title":"Clinical validity of A\u03b242, tau, and phospho-tau in the cerebrospinal fluid as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework","volume":"52","author":"Mattsson","year":"2017","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib69","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib70","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1212\/WNL.0b013e31826e2696","article-title":"Indicators of amyloid burden in a population-based study of cognitively normal elderly","volume":"79","author":"Mielke","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib71","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1212\/01.wnl.0000228230.26044.a4","article-title":"[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease","volume":"67","author":"Mintun","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib72","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1212\/WNL.41.4.479","article-title":"The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease","volume":"41","author":"Mirra","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib73","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/brain\/awn320","article-title":"Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects","volume":"132","author":"Mormino","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib74","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ana.21843","article-title":"APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging","volume":"67","author":"Morris","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib75","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/joim.12199","article-title":"Harmonized diagnostic criteria for Alzheimer's disease: recommendations","volume":"275","author":"Morris","year":"2014","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib76","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.neuroimage.2013.04.048","article-title":"Mapping the effects of ApoE4, age and cognitive status on 18F-florbetapir PET measured regional cortical patterns of beta-amyloid density and growth","volume":"78","author":"Murphy","year":"2013","journal-title":"Neuroimage"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib77","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/brain\/awv050","article-title":"Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum","volume":"138","author":"Murray","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib78","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3174\/ajnr.A4281","article-title":"Use of standardized uptake value ratios decreases interreader variability of [F-18]Florbetapir pet brain scan interpretation","volume":"36","author":"Nayate","year":"2015","journal-title":"Am. J. Neuroradiol."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib79","series-title":"ClinicalTrials.gov [Internet]","article-title":"Clinical evaluation of florbetapir F 18 (18F-AV-45)","year":"2000"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib80","series-title":"ClinicalTrials.gov [Internet]","article-title":"Investigating the clinical consequences of flutemetamol-PET-scanning","year":"2000"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib81","series-title":"ClinicalTrials.gov [Internet]","article-title":"Imaging Dementia\u2014Evidence for Amyloid Scanning (IDEAS) study (IDEAS)","year":"2000"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib82","series-title":"ClinicalTrials.gov [Internet]","article-title":"Impact of FBB PET amyloid imaging in change of diagnosis in patients with AD","year":"2000"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib83","series-title":"ClinicalTrials.gov [Internet]","article-title":"Implications for management of PET amyloid classification technology (IMPACT)","year":"2000"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib84","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2967\/jnumed.109.063305","article-title":"Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease","volume":"50","author":"Nelissen","year":"2009","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib85","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/brain\/awt142","article-title":"Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue","volume":"136","author":"Ni","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib86","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00259-012-2237-2","article-title":"A\u00a0European multicentre PET study of fibrillar amyloid in Alzheimer's disease","volume":"40","author":"Nordberg","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib87","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1136\/jnnp-2014-308094","article-title":"Abeta imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study","volume":"86","author":"Ong","year":"2015","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib88","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jalz.2012.07.003","article-title":"Impact of molecular imaging on the diagnostic process in a memory clinic","volume":"9","author":"Ossenkoppele","year":"2013","journal-title":"Alzheimer's Demen."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib89","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1212\/WNL.0b013e31827f0889","article-title":"Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia","volume":"80","author":"Ossenkoppele","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib90","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1001\/jama.2015.4669","article-title":"Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis","volume":"313","author":"Ossenkoppele","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib91","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s00259-015-3067-9","article-title":"Cognitive and functional patterns of nondemented subjects with equivocal visual amyloid PET findings","volume":"42","author":"Payoux","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib92","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/jnci\/93.14.1054","article-title":"Phases of biomarker development for early detection of cancer","volume":"93","author":"Pepe","year":"2001","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib93","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/sj.jcbfm.9600146","article-title":"Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B","volume":"25","author":"Price","year":"2005","journal-title":"J.\u00a0Cereb. Blood flow Metab."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib94","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/brain\/awp326","article-title":"Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden","volume":"133","author":"Rabinovici","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib95","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1212\/WNL.0b013e31823b9c5e","article-title":"Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD","volume":"77","author":"Rabinovici","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib96","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.1073\/pnas.0900345106","article-title":"Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease","volume":"106","author":"Reiman","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib97","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00401-012-1051-z","article-title":"[(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid beta detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies","volume":"124","author":"Rinne","year":"2012","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib98","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1474-4422(08)70001-2","article-title":"Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism","volume":"7","author":"Rowe","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib101","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/ana.24040","article-title":"Predicting Alzheimer disease with beta-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing","volume":"74","author":"Rowe","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib100","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.neurobiolaging.2010.04.007","article-title":"Amyloid imaging results from the Australian imaging, biomarkers and lifestyle (AIBL) study of aging","volume":"31","author":"Rowe","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib99","series-title":"Society of Nuclear Medicine Meeting","article-title":"Test\u2013retest variability of high and low specific activity [18F]BAY 94-9172 in Alzheimer's disease and normal ageing","author":"Rowe","year":"2009"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib102","doi-asserted-by":"crossref","first-page":"880","DOI":"10.2967\/jnumed.112.114785","article-title":"Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for beta-amyloid imaging in aging and dementia","volume":"54","author":"Rowe","year":"2013","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib103","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","article-title":"Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study","volume":"11","author":"Sabri","year":"2015","journal-title":"Alzheimer's Demen."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib104","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s00259-013-2656-8","article-title":"Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in\u00a0vivo","volume":"41","author":"Saint-Aubert","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib105","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1212\/WNL.0000000000000032","article-title":"Practical utility of amyloid and FDG-PET in an academic dementia center","volume":"82","author":"Sanchez-Juan","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib106","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3233\/JAD-132783","article-title":"Cortical (1)(1)C-PIB uptake is associated with age, APOE genotype, and gender in \u201chealthy aging\u201d","volume":"41","author":"Scheinin","year":"2014","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib107","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1001\/jamaneurol.2015.1633","article-title":"Comparison of visual and quantitative florbetapir F 18 positron emission tomography analysis in predicting mild cognitive impairment outcomes","volume":"72","author":"Schreiber","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib108","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00019442-200201000-00004","article-title":"Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease","volume":"10","author":"Shoghi-Jadid","year":"2002","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib109","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1056\/NEJMoa054625","article-title":"PET of brain amyloid and tau in mild cognitive impairment","volume":"355","author":"Small","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib110","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1750-3639.2006.00006.x","article-title":"The 2,6-disubstituted naphthalene derivative FDDNP labeling reliably predicts Congo red birefringence of protein deposits in brain sections of selected human neurodegenerative diseases","volume":"16","author":"Smid","year":"2006","journal-title":"Brain Pathol."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib111","first-page":"228","volume":"52","author":"Sonni","year":"2017","journal-title":"Aging"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib112","first-page":"167","article-title":"The Geneva Task Force for the Roadmap of Alzheimer\u2019s Biomarkers, Maturity of medial temporal atrophy as a biomarker for Alzheimer\u2019s disease in the context of a structured 5-phase development framework, Neurobiol","volume":"52","author":"Ten Kate","year":"2017","journal-title":"Aging"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib113","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jalz.2015.05.018","article-title":"[(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-beta pathology","volume":"11","author":"Thal","year":"2015","journal-title":"Alzheimers Demen."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib114","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","article-title":"Phases of A beta-deposition in the human brain and its relevance for the development of AD","volume":"58","author":"Thal","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib115","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000335381","article-title":"Combination of biomarkers: PET [18F]flutemetamol imaging and structural MRI in dementia and mild cognitive impairment","volume":"10","author":"Thurfjell","year":"2012","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib116","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.2967\/jnumed.114.142109","article-title":"Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads","volume":"55","author":"Thurfjell","year":"2014","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib117","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neurobiolaging.2013.06.018","article-title":"Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia","volume":"35","author":"Trzepacz","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib119","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.neuroimage.2012.09.015","article-title":"Binary classification of (1)(8)F-flutemetamol PET using machine learning: comparison with visual reads and structural MRI","volume":"64","author":"Vandenberghe","year":"2013","journal-title":"Neuroimage"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib118","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ana.22068","article-title":"18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial","volume":"68","author":"Vandenberghe","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib122","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00259-012-2088-x","article-title":"Comparison of 11C-PiB and 18F-florbetaben for Abeta imaging in ageing and Alzheimer's disease","volume":"39","author":"Villemagne","year":"2012","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib120","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2967\/jnumed.111.089730","article-title":"Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias","volume":"52","author":"Villemagne","year":"2011","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib121","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ana.22248","article-title":"Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease","volume":"69","author":"Villemagne","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib123","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/brain\/awv112","article-title":"Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation","volume":"138","author":"Villeneuve","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib124","series-title":"Alzheimer's Association International Conference","article-title":"Are low levels of PIB-PET signal clinically significant?","author":"Villeneuve","year":"2015"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib125","doi-asserted-by":"crossref","first-page":"8612","DOI":"10.1523\/JNEUROSCI.4612-13.2014","article-title":"Gene-environment interactions: lifetime cognitive activity, APOE genotype, and beta-amyloid burden","volume":"34","author":"Wirth","year":"2014","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib126","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1001\/archneurol.2011.153","article-title":"Association between in\u00a0vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in\u00a0vivo cerebral cortical histopathology","volume":"68","author":"Wolk","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib127","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1136\/jnnp-2012-302548","article-title":"Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography","volume":"83","author":"Wolk","year":"2012","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib128","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2967\/jnumed.109.069088","article-title":"In\u00a0vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18)","volume":"51","author":"Wong","year":"2010","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib129","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/gps.4235","article-title":"Low amyloid-beta deposition correlates with high education in cognitively normal older adults: a pilot study","volume":"30","author":"Yasuno","year":"2015","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.neurobiolaging.2016.07.012_bib130","first-page":"5","article-title":"A\u00a0systematic review and meta-analysis of (18)F-labeled amyloid imaging in Alzheimer's disease","volume":"1","author":"Yeo","year":"2015","journal-title":"Alzheimers Demen."}],"container-title":["Neurobiology of Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458016301488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458016301488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T14:00:32Z","timestamp":1762264832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197458016301488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":130,"alternative-id":["S0197458016301488"],"URL":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2016.07.012","relation":{},"ISSN":["0197-4580"],"issn-type":[{"value":"0197-4580","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Aging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2016.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}